CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of Hematology (ASH) Annual Meeting.

source https://medicalxpress.com/news/2022-12-car-t-cell-patients-lymphoma-brain-spinal.html